Savara Inc. announced the U.S. launch of the aPAP ClearPath™ Dried Blood Spot (DBS) Test, an advancement in diagnosing autoimmune pulmonary alveolar proteinosis (aPAP). This new test is an evolution of the company's initial serum-based assay.
The DBS test is designed to aid in the diagnosis of aPAP, a rare autoimmune lung disease caused by antibodies targeting GM-CSF. It requires only a finger-prick blood sample, offering a simpler and less invasive method for patient testing.
This diagnostic tool is expected to increase awareness and provide a quicker path to diagnosis for patients with this debilitating condition. An accurate and accessible diagnostic test is crucial for identifying the patient population that could benefit from MOLBREEVI.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.